Video
Dr. Ramaprasad Srinivasan on the HIF-2α inhibitor MK-6482 in VHL-associated RCC
Author(s):
Over 90% of patients in a phase 2 trial had at least some decrease in the size of target lesions.
Dr. Ramaprasad Srinivasan, MD, PhD, Urologic Oncology Branch, National Cancer Institute, discusses a phase 2 study of the investigational HIF-2α inhibitor MK-6482 in patients with Von Hippel-Lindau–associated renal cell carcinoma (RCC).
Results from the study shared during the 2020 Society of Urologic Oncology Annual Meeting showed that at a median follow-up of 68.7 weeks (range, 18.3-104.7), the objective response rate (ORR) in RCC lesions among 60 evaluable patients was 36.1%, comprising 22 confirmed partial responses (PRs). There were also 7 unconfirmed PRs. Overall, 91.8% (n = 56) of patients had at least some decrease in the size of target lesions.
Clinical activity with MK-6482 was also observed in non-RCC lesions. The confirmed ORR in pancreatic lesions was 63.9%, including 4 complete responses. The confirmed ORR in brain hemangioblastomas was 30.2%, with a CR rate of 11.6%. Also, 11 (68.8%) of 15 patients with retinal lesions demonstrated improvement in these lesions, with the 4 other patients reaching stable disease.
